Gilead Sciences, Inc. (NASDAQ: GILD) Stock Competitors & Peer Comparison
See GILD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GILD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GILD | $147.81 | +0.14% | 178.1B | -367.79 | -$0.39 | +2.22% |
| LLY | $1,269.25 | -0.87% | 1.2T | 39.56 | $31.49 | +0.53% |
| JNJ | $271.49 | -0.70% | 645.3B | 24.96 | $10.73 | +1.95% |
| ABBV | $266.18 | +0.08% | 462.6B | 25.69 | $10.19 | +2.60% |
| MRK | $153.51 | +0.86% | 368.5B | 46.48 | $3.21 | +2.23% |
| NVS | $159.18 | -0.71% | 297B | 17.98 | $8.69 | +3.03% |
| AZN | $166.75 | +1.09% | 255.2B | 17.77 | $9.26 | +1.27% |
| AMGN | $440.57 | -0.40% | 234.1B | 19.39 | $22.37 | +2.26% |
| NVO | $46.97 | +1.05% | 205.1B | 11.49 | $4.02 | +2.51% |
| PFE | $28.22 | -0.09% | 158.5B | 9.12 | $3.05 | +6.15% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
GILD vs LLY Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while LLY trades at $1,269.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas LLY's P/E ratio is 39.56. In terms of profitability, GILD's ROE is -0.16%, compared to LLY's ROE of +0.93%. Regarding short-term risk, GILD is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for GILD.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
GILD vs JNJ Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, JNJ has a market cap of 645.3B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while JNJ trades at $271.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas JNJ's P/E ratio is 24.96. In terms of profitability, GILD's ROE is -0.16%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GILD is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for GILD.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
GILD vs ABBV Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, ABBV has a market cap of 462.6B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while ABBV trades at $266.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas ABBV's P/E ratio is 25.69. In terms of profitability, GILD's ROE is -0.16%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, GILD is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for GILD.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
GILD vs MRK Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, MRK has a market cap of 368.5B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while MRK trades at $153.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas MRK's P/E ratio is 46.48. In terms of profitability, GILD's ROE is -0.16%, compared to MRK's ROE of +0.07%. Regarding short-term risk, GILD is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for GILD.Check MRK's competition here
Novartis AG (NYSE: NVS)
GILD vs NVS Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, NVS has a market cap of 297B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while NVS trades at $159.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas NVS's P/E ratio is 17.98. In terms of profitability, GILD's ROE is -0.16%, compared to NVS's ROE of +0.30%. Regarding short-term risk, GILD is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for GILD.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
GILD vs AZN Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, AZN has a market cap of 255.2B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while AZN trades at $166.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas AZN's P/E ratio is 17.77. In terms of profitability, GILD's ROE is -0.16%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GILD is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for GILD.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
GILD vs AMGN Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, AMGN has a market cap of 234.1B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while AMGN trades at $440.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas AMGN's P/E ratio is 19.39. In terms of profitability, GILD's ROE is -0.16%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GILD is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for GILD.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
GILD vs NVO Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, NVO has a market cap of 205.1B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while NVO trades at $46.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas NVO's P/E ratio is 11.49. In terms of profitability, GILD's ROE is -0.16%, compared to NVO's ROE of +0.59%. Regarding short-term risk, GILD is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for GILD.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
GILD vs PFE Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, PFE has a market cap of 158.5B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while PFE trades at $28.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas PFE's P/E ratio is 9.12. In terms of profitability, GILD's ROE is -0.16%, compared to PFE's ROE of +0.05%. Regarding short-term risk, GILD is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for GILD.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
GILD vs BMY Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, BMY has a market cap of 133.8B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while BMY trades at $67.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas BMY's P/E ratio is 11.04. In terms of profitability, GILD's ROE is -0.16%, compared to BMY's ROE of +0.47%. Regarding short-term risk, GILD is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for GILD.Check BMY's competition here
Sanofi (NASDAQ: SNY)
GILD vs SNY Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, SNY has a market cap of 108.4B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while SNY trades at $46.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas SNY's P/E ratio is 9.84. In terms of profitability, GILD's ROE is -0.16%, compared to SNY's ROE of +0.06%. Regarding short-term risk, GILD is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for GILD.Check SNY's competition here
GSK plc (NYSE: GSK)
GILD vs GSK Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, GSK has a market cap of 104.1B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while GSK trades at $52.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas GSK's P/E ratio is 11.22. In terms of profitability, GILD's ROE is -0.16%, compared to GSK's ROE of +0.24%. Regarding short-term risk, GILD is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for GILD.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
GILD vs BIIB Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, BIIB has a market cap of 31.7B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while BIIB trades at $218.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas BIIB's P/E ratio is 13.53. In terms of profitability, GILD's ROE is -0.16%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, GILD is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for GILD.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
GILD vs ZTS Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, ZTS has a market cap of 31.5B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while ZTS trades at $77.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas ZTS's P/E ratio is 11.40. In terms of profitability, GILD's ROE is -0.16%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, GILD is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for GILD.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
GILD vs HZNP Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GILD's ROE is -0.16%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GILD is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for GILD.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
GILD vs GRFS Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while GRFS trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas GRFS's P/E ratio is 9.18. In terms of profitability, GILD's ROE is -0.16%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GILD is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for GILD.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
GILD vs OGN Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while OGN trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas OGN's P/E ratio is 4.10. In terms of profitability, GILD's ROE is -0.16%, compared to OGN's ROE of +0.23%. Regarding short-term risk, GILD is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for GILD.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
GILD vs CELG-RI Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while CELG-RI trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GILD's ROE is -0.16%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, GILD is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for GILD.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
GILD vs CTOR Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while CTOR trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas CTOR's P/E ratio is -1.62. In terms of profitability, GILD's ROE is -0.16%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, GILD is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for GILD.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
GILD vs SCLX Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, SCLX has a market cap of 49.2M. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while SCLX trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas SCLX's P/E ratio is -0.15. In terms of profitability, GILD's ROE is -0.16%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GILD is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for GILD.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
GILD vs SCLXW Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, SCLXW has a market cap of 44.7M. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GILD's ROE is -0.16%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GILD is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for GILD.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
GILD vs MIRA Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, MIRA has a market cap of 29.8M. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while MIRA trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas MIRA's P/E ratio is -0.49. In terms of profitability, GILD's ROE is -0.16%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, GILD is more volatile compared to MIRA. This indicates higher risk in terms of short-term price fluctuations for GILD.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
GILD vs BDSIW Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, GILD's ROE is -0.16%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GILD is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for GILD.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
GILD vs CRXT Comparison August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GILD stands at 178.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GILD is priced at $147.81 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GILD currently has a P/E ratio of -367.79, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GILD's ROE is -0.16%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GILD is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for GILD.Check CRXT's competition here